-
VRNA Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Verona Pharma (VRNA)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 336.04 mm | 336.04 mm | 336.04 mm | 336.04 mm | 336.04 mm | 336.04 mm |
Cash burn (monthly) | 22.85 mm | (no burn) | 14.24 mm | 13.24 mm | 20.89 mm | 8.65 mm |
Cash used (since last report) | 98.74 mm | n/a | 61.51 mm | 57.18 mm | 90.23 mm | 37.36 mm |
Cash remaining | 237.30 mm | n/a | 274.53 mm | 278.86 mm | 245.81 mm | 298.68 mm |
Runway (months of cash) | 10.4 | n/a | 19.3 | 21.1 | 11.8 | 34.5 |
13F holders | Current |
---|---|
Total holders | 153 |
Opened positions | 45 |
Closed positions | 21 |
Increased positions | 41 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 1.84 tn |
Total shares | 155.86 mm |
Total puts | 683.70 k |
Total calls | 629.20 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities Fund IV | 44.68 mm | $452.59 mm |
Vivo Ventures VI | 23.49 mm | $157.88 mm |
Vivo Ventures Vii | 20.25 mm | $692.44 mm |
Perceptive Advisors | 6.32 mm | $181.71 bn |
NEA Management | 5.58 mm | $160.67 bn |
Ra Capital Management | 5.01 mm | $144.13 bn |
Maverick Capital | 4.22 mm | $121.29 bn |
Vivo Capital | 3.55 mm | $102.13 bn |
Frazier Life Sciences Management | 3.38 mm | $97.36 bn |
Deep Track Capital | 3.18 mm | $91.49 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Feb 25 | Kathleen A. Rickard | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.1625 | 33,240 | 238.08 k | 2,688,240 |
3 Feb 25 | David Zaccardelli | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.1625 | 166,728 | 1.19 mm | 14,238,024 |
3 Feb 25 | Mark W Hahn | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.1625 | 166,888 | 1.20 mm | 13,326,848 |
1 Feb 25 | Kathleen A. Rickard | Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 2,721,480 |
1 Feb 25 | David Zaccardelli | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 14,404,752 |
1 Feb 25 | Mark W Hahn | Ordinary Shares | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 13,493,736 |
6 Dec 24 | Mark W Hahn | Ordinary Shares | Sell | Dispose S | No | Yes | 5.0091 | 183,728 | 920.31 k | 13,293,736 |
6 Dec 24 | David Zaccardelli | Ordinary Shares | Sell | Dispose S | No | Yes | 5.0086 | 162,800 | 815.40 k | 14,204,752 |
5 Dec 24 | Mark W Hahn | Ordinary Shares | Sell | Dispose S | No | Yes | 5.0061 | 640,048 | 3.20 mm | 13,477,464 |
5 Dec 24 | David Zaccardelli | Ordinary Shares | Sell | Dispose S | No | Yes | 5.0061 | 640,264 | 3.21 mm | 14,367,552 |